CC-115 induces apoptosis in CLL cells from distinct prognostic groups. (A-B) CLL cells were incubated with 0.001 to 10 μM CC-115, CC-214, CC-292, idelalisib, or NU7441 for 48 hours. (A) Viability was assessed by DiOC6/PI staining, and (B) specific apoptosis was calculated (“Materials and methods”). Results are shown as mean ± SEM (n = 23; patients 6, 7, 8A, 21-31, 32A,B, 33A,B, 34A, 35A, and 36-38). (C) CLL cells were incubated with 1 µM CC-115, CC-214, NU7441, or CC-214 + NU7441 for 48 hours. Results are shown as mean ± SEM (n = 11; patients 8B, 23, and 39-46). (D) CLL cells of patients of distinct prognostic CLL groups, wild type (n = 23; patients 6, 7, 8A, 21-31, 32A,B, 33A,B, 34A, 35A, and 36-38), ATM mutated (n = 10; patients 2C and 47-55), p53 mutated (n = 6; patients 56-61), SF3B1 mutated (n = 4; patients 62-65), and NOTCH1 mutated (n = 3; patients 66-68) were incubated with CC-115 for 48 hours. Results are shown as mean ± SEM. (E) CLL cells were cultured with 20 µM Q-VD or 5 mM NAC and with increasing concentrations of CC-115 for 48 hours. Results are shown as mean ± SEM (n = 3; patients 21, 33B, and 31). (F) CLL cells were cultured with 6.25 µM chlorambucil, 6.25 µM bendamustine, 0.1 µM CC-115, or the combination of 6.25 µM chlorambucil/bendamustine and 0.1 µM CC-115 for 48 hours. Results are shown as mean ± SEM (n = 5; patients 2C, 19B, 29, 37, and 69). *P < .05, **P < .01, ***P < .001 (1-way ANOVA).